Saturday, October 8, 2016

India's Biosimilars market is expected to cross $40 Billion by 2030

Biosimilars presents a $240 Billion global opportunity for Indian Pharmaceuticals Industry while domestic market is expected to cross $40 Billion by 2030 ” says ASSOCHAM-SATHGURU Report released by Prof. D. Swaminadhan, President & Director General, Jawaharlal Nehru Institute of Advanced Studies (JNIAS) at ASSOCHAM-Department of Pharmaceuticals Conference on BioPharma at Hyderabad

Indian Biosimilars industry is close to $ 300 Million in 2015. Domestic sales are close to $ 250 Million growing at CAGR of 14% while, exports contributed close to $ 51 Million. However, with the introduction of a new regulatory policy in India and increased affordability that Biosimilars offer, the domestic market is expected to grow at an accelerated pace and reach the target of $40 Billion by 2030 & will command ~20% share in global market says ASSOCHAM-SATHGURU Report released during ASSOCHAM and Department of Pharmaceuticals, Government of India Conference on “BioPharma: Biosimilars and Biogenerics; Emerging Investment Destination” at Hyderabad.